All News

EULAR,poster

EULAR 2021 – Day 1 Report

d Jack Cush, MD

After the opening ceremonies and keynote speaker there were several enticing sessions and a plenary session full of great research and presentations.  Here are a few of the highlights that I saw.

Read Article
TNFi use associated with ⬇️ radiographic sacroilitis progression in patients with AxSpA ⭐️effect becomes evident between 2 and 4 years after treatment Abs#OP0137 #EULAR2021 @RheumNow

Robert B Chao, MD doctorRBC ( View Tweet)

Machine learning to model risk for SSc-ILD ⭐️predict time to lung function decline ⭐️needs larger sample size Abs#OP0150 #EULAR2021 @RheumNow

Robert B Chao, MD doctorRBC ( View Tweet)

OP0186 #EULAR2021 by Dr. Mariele Gatto. Anti-cancer effect of immunotherapy with ICI is believed to be mediated by CD8 positive Tc cells. It is not known if other cells get activated. This study looks at B cells. Transitional B cells ⬆️ in ICI induced arthritis (CP-IA). /TK https://t.co/szFF81SKVL
ARD & RMD Open ARD_BMJ ( View Tweet)
No requirement to stop cDMARDs before surgery. For biologics stop 1 dose before and restart 14 days post op, JAKi stop 7 days before, restart 14 days post op, glucocorticoids >10mg/day increases risk of infection in #rheumatoidarthritis Michael D George #EULAR2021

Dr. Antoni Chan synovialjoints ( View Tweet)

#POS0093 Collaborative registry studies are to be encouraged! BUT @k_lauper outlines the heterogenity between registries concerning #AE reporting - Jak-pot study - 18 registries with #RA patients on #tofacitinib - Rates of discontinuation vary across registry #EULAR2021 @RheumNow https://t.co/oczJAG8hzv
Paul Studenic Stiddyo ( View Tweet)
SPACING trial OP0138 at #EULAR2021 ⭐️RCT by the French showing non-inferiority of spacing TNFi in r-axSpA pts w/ LDA (BASDAI<4 x 6mo) ⭐️ 88% in spacing group remained w/ LDA vs 91.5% in standard tx ⭐️ADA, CTZ, GOL, IFX spaced by 1w intervals. ETN by 3-4d & 1w. @RheumNow

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

Immune events with #checkpointinhibitors 🧐which are the most common? Interesting talk by Maria Suarez-Almazor at #EULAR2021 @eular_org https://t.co/PFPPL4cqOG
EMEUNET EMEUNET ( View Tweet)
You put a pt on a #Jaki What is most likely infection that will occur? #EULAR2021 @RheumNow @eular_org

Janet Pope Janetbirdope ( View Tweet)

So how do irAEs work? Dr. Anne Bass @lovetolearn27 @HSpecialSurgery gives #EULAR2021 a possible conceptual framework @LCalabreseDO @CCalabreseDO @cappelliMD @got_rheum @MarieKostine and so many other good people! @RheumNow https://t.co/5eOZDwkGO6
David Liew drdavidliew ( View Tweet)
An original way of differentiating RA from PsA! The shape of the second MCP in HR-pQCT is enough to train a neural network with high accuracy for recognition of -HC 94% -RA 84% -PsA 89% and an AUC of 91%. #EULAR2021 @RheumNow #OP0145 https://t.co/BrwFQpX310
Aurelie Najm AurelieRheumo ( View Tweet)
Presentation 3480 at #EULAR2021. Your patient is on CellCept, has negative COVID spike IgG and IgM antibodies after vaccination with mRNA vaccination x2. What do you counsel on this test? @RheumNow

Eric Dein ejdein1 ( View Tweet)

Anifrolumab pooled TULIP-1&-2 data on rash and arthritis in SLE more effective in pts with high IFN signals (pts with low IFN may benefit, but they had less rash but more arthritis)- Dr. J Merrill #OP0131 #EULAR2021 @rheumnow

k dao KDAO2011 ( View Tweet)

@KDAO2011 @RheumNow @LupusDocLim @Lupusdoc1 @LupusMD Check this! (top left corner) #HCQ #Lupus #EULAR2021 Link: https://t.co/RQcWoStJtP https://t.co/96l1FvYDQH

Links:

Laurent ARNAUD Lupusreference ( View Tweet)
⬆️prevalence of HCQ retinopathy: Kaiser Permanente 676 pts retrospect study #OP0133 👉6.8% (n=46) had HCQ retinopathy w/ risks: 👉age>80 (OR 3.83) 👉h/o atherosclerosis (OR 2.99), 👉cum. dose >2000 mg (OR 15.8) 👉10-15 yrs use (OR 4.44) 👉>15 yrs (OR 19) #EULAR2021 @rheumnow https://t.co/QA8HHXdnjL
k dao KDAO2011 ( View Tweet)
News: Featured Abstracts from Industry at EULAR 2021 https://t.co/hIBYUdHTLf https://t.co/LTTJ3WPl7X

Links:

Dr. John Cush RheumNow ( View Tweet)
#EULAR Presentation 3478: Infection risk with surgeries: ⭐️Continue conventional DMARD ⭐️Some risk with biologics, may be confounder and no association with timing of infusions ⭐️Steroids are major risk factor! Esp >10 mg/d ⭐️Recommendations shown ⭐️Address other risks! @rheumnow https://t.co/Bi02d4p9Mw
Eric Dein ejdein1 ( View Tweet)
COAST-Y 2 yr results: In r- and nr-axSpA, IXE tx led to consistent & sustained long-term improvements in disease activity & QoL. No new safety signals. #EULAR2021 poster #POS0912 @RheumNow https://t.co/W2YoyA4K14 https://t.co/lv0GLU2WTF

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
#EULAR2021: Great talk by Dr. McFarland recapping the evidence for managing fibromyalgia. ➡️Over a 6 month time period, costs were significantly lower for people receiving psychological therapies compared to those receiving usual care as shown by Cabral et al. @RheumNow https://t.co/RAkUSeNESy
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Which drug are you most excited about changing future treatments in SLE? #EULAR2021 @RheumNow

Eric Dein ejdein1 ( View Tweet)

×